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A BS TR AC T
BACKGROUND
Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis 
(JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, 
anti–interleukin-1β monoclonal antibody, in two trials.
METHODS
In trial 1, we randomly assigned patients, 2 to 19 years of age, with systemic JIA 
and active systemic features (fever; ≥2 active joints; C-reactive protein, >30 mg per 
liter; and glucocorticoid dose, ≤1.0 mg per kilogram of body weight per day), in a 
double-blind fashion, to a single subcutaneous dose of canakinumab (4 mg per kilo-
gram) or placebo. The primary outcome, termed adapted JIA ACR 30 response, was 
defined as improvement of 30% or more in at least three of the six core criteria for 
JIA, worsening of more than 30% in no more than one of the criteria, and resolution 
of fever. In trial 2, after 32 weeks of open-label treatment with canakinumab, pa-
tients who had a response and underwent glucocorticoid tapering were randomly 
assigned to continued treatment with canakinumab or to placebo. The primary 
outcome was time to flare of systemic JIA.
RESULTS
At day 15 in trial 1, more patients in the canakinumab group had an adapted JIA 
ACR 30 response (36 of 43 [84%], vs. 4 of 41 [10%] in the placebo group; P<0.001). 
In trial 2, among the 100 patients (of 177 in the open-label phase) who underwent 
randomization in the withdrawal phase, the risk of flare was lower among patients 
who continued to receive canakinumab than among those who were switched to pla-
cebo (74% of patients in the canakinumab group had no flare, vs. 25% in the pla-
cebo group, according to Kaplan–Meier estimates; hazard ratio, 0.36; P = 0.003). 
The average glucocorticoid dose was reduced from 0.34 to 0.05 mg per kilogram per 
day, and glucocorticoids were discontinued in 42 of 128 patients (33%). The macro-
phage activation syndrome occurred in 7 patients; infections were more frequent 
with canakinumab than with placebo.
CONCLUSIONS
These two phase 3 studies show the efficacy of canakinumab in systemic JIA with 
active systemic features. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, 
NCT00889863 and NCT00886769.)
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Systemic juvenile idiopathic arthri-tis (JIA), the most severe JIA subtype, is characterized by chronic arthritis; intermit-
tently high, spiking temperatures; maculopapular 
rash; hepatosplenomegaly; lymphadenopathy; 
serositis; and a marked increase in the level of 
acute-phase reactants.1-3 Complications of sys-
temic JIA include growth impairment, osteopo-
rosis, and the potentially lethal macrophage acti-
vation syndrome.4-6
Until recently, systemic JIA was considered a 
therapeutic orphan, since the principal effective 
treatment was glucocorticoids, with their known 
toxicity and long-term growth and bone sequelae.7 
Other therapeutic options include nonsteroidal 
antiinflammatory drugs (NSAIDs), methotrexate, 
and biologic agents. Both interleukin-68-10 and, 
more recently, interleukin-111-14 have been found 
to be central to the pathogenesis of systemic JIA. 
However, reported evidence of the benefits of 
anti–interleukin-1 treatment remains limited.
Canakinumab is a fully human, anti–inter-
leukin-1β monoclonal antibody that selectively 
binds to interleukin-1β, inactivating its signal-
ing.15-17 Data from a recent phase 2 trial led to 
the dose of 4 mg per kilogram of body weight 
per month (maximum dose, 300 mg), adminis-
tered subcutaneously, that was used in this 
phase 3 trial.18 We assessed the efficacy and 
safety of canakinumab for the treatment of sys-
temic JIA with active systemic features in two 
phase 3, randomized, double-blind, placebo-
controlled studies.
ME THODS
PATIENTS
Eligible patients were 2 to 19 years of age, with 
systemic JIA,19,20 including active systemic features 
and arthritis (intermittently spiking temperatures 
of >38°C, ≥2 active joints,21 and C-reactive protein 
level of >30 mg per liter [normal value, <10 mg 
per liter]). Background therapy with a prednisone 
equivalent of up to 1.0 mg per kilogram per day 
and stable doses of NSAIDs and methotrexate 
(≤20 mg per square meter of body-surface area 
per week) were permitted. Major exclusion crite-
ria were concomitant treatment with another bio-
logic agent or disease-modifying drug (with a 
washout of ≥5 half-lives), diagnosis of the macro-
phage activation syndrome6 within 6 months be-
fore enrollment, active tuberculosis, and live-virus 
vaccination within 3 months before enrollment.
STUDY DESIGN
Patients were enrolled in the two trials between 
July 2009 and December 2010 at 63 centers that 
were members of the Paediatric Rheumatology 
International Trials Organisation (PRINTO)22 and 
the Pediatric Rheumatology Collaborative Study 
Group (PRCSG). Trial 1 was a 29-day, single-dose, 
randomized, double-blind, placebo-controlled 
study. Patients with persistent fever (temperature, 
>38°C) after day 3 were made aware of the study 
assignment at the physician’s discretion and, if 
they were receiving placebo, were permitted to 
enroll in trial 2. In trial 1, patients who had a 
response to canakinumab at day 15, according to 
an adaptation of the JIA American College of 
Rheumatology (ACR) 30 response (adapted JIA 
ACR 30 response, defined as the absence of fever 
plus improvement of ≥30% in three or more of 
the six variables of the JIA core set,22 with no 
more than one variable worsening by >30% at 
day 1523,24), were immediately enrolled in trial 2 
on day 29 (Fig. S1 and S2 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org).
Trial 2 used a two-part withdrawal design.24,25 
The first part was an open-label phase in which 
eligible patients were treated with canakinumab 
every 4 weeks for 12 to 32 weeks. For patients 
who were receiving glucocorticoids at enroll-
ment, glucocorticoid tapering according to a 
standardized procedure was permitted from 
week 9 through week 28, if there was at least an 
adapted JIA ACR 50 response (indicating the 
absence of fever and an improvement of ≥50% in 
at least three of the six core criteria for JIA, with 
a worsening of >30% in no more than one of the 
criteria). The second part was a withdrawal phase 
in which patients who had at least an adapted JIA 
ACR 30 response that was sustained and who 
were not receiving glucocorticoids or who had 
undergone successful glucocorticoid tapering and 
were receiving a stable dose of glucocorticoids 
were randomly assigned in a 1:1 ratio, in a double-
blind fashion, to continued treatment with 
canakinumab or to placebo (for glucocorticoid-
tapering recommendations and eligibility criteria 
for randomization, see Table S1 in the Supple-
mentary Appendix). In this withdrawal phase, 
patients who had a disease flare according to a 
prespecified definition were treated again with 
canakinumab in an open-label fashion. All pa-
tients who did not undergo glucocorticoid taper-
ing, who had no response during the open-label 
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phase, or who had a flare during the withdrawal 
phase could enter the ongoing long-term, open-
label extension phase of the trial. In both trials, 
randomization was computer-generated by means 
of an interactive voice-response system, with a 
block size of two.
STUDY OVERSIGHT
The protocols of the two trials were approved by 
the local ethics committees, and written informed 
consent and assent were obtained. The trials 
were conducted in accordance with Good Clini-
cal Practice guidelines and the study protocols, 
available at NEJM.org.
The studies were designed jointly by four of 
the academic authors and the sponsor (Novartis 
Pharma), with data collected by the PRINTO and 
PRCSG investigators. The sponsor was respon-
sible for the overall management of the study 
and the data analysis.
The initial draft of the manuscript was writ-
ten by the first author, with critical revision by 
three of the academic authors; these four authors 
decided to submit the manuscript for publica-
tion. All authors contributed to the revision. All 
the academic authors vouch for the completeness 
and veracity of the data and analyses, as well as 
for the fidelity of the study to the protocol. Edito-
rial assistance was provided by a medical writer 
paid by the sponsor.
ASSESSMENT AND OUTCOMES
Clinical assessments were performed at days 3, 
15, and 29 and every 28 days thereafter. The pri-
mary outcome for trial 1 was the proportion of 
patients with an adapted JIA ACR 30 response. 
Resolution of fever was defined as the documented 
absence of fever due to systemic JIA (body tem-
perature, ≤38°C) in the week preceding the as-
sessment, according to a paper diary. The six JIA 
core-set variables (with higher values indicating 
higher disease activity) were the number of joints 
with active arthritis (0 to 73 joints),21 the number of 
joints with limited range of motion (0 to 69 joints), 
the physician’s global assessment of disease ac-
tivity (on a 100-mm visual-analogue scale, with 
higher scores indicating more disease activity), the 
parent’s global assessment of the patient’s overall 
well-being (on a 100-mm visual-analogue scale, 
with higher scores indicating worse overall well-
being), an assessment of physical function with 
the use of the cross-culturally adapted and vali-
dated version of the Disability Index of the Child-
hood Health Assessment Questionnaire (CHAQ-DI; 
on a scale of 0 to 3, with higher scores indicating 
greater disability), and a C-reactive protein level 
standardized to 0 to 10 mg per liter.24,26-28 An in-
dependent joint examiner was required at each 
center; 41 of the 63 centers (65%) had at least one 
joint examiner who was certified by PRINTO or 
PRCSG.
In the open-label phase of trial 2, the objec-
tive was to determine whether at least 25% of the 
patients who were being treated with glucocorti-
coids could have their dose tapered (Table S1 in 
the Supplementary Appendix); the expected taper-
ing frequency was established by consensus of 
the steering committee. In the withdrawal phase, 
the objective was to show that the time to flare 
was longer with canakinumab than with placebo. 
Flare was defined as the recurrence of fever last-
ing for 2 or more consecutive days; a worsening 
of 30% or more in three or more of the six vari-
ables of the JIA core set, with no more than one 
variable improving by 30% or more (minimum 
contingencies included worsening in at least two 
joints with active or limited disease, at least a 
20-mm worsening on the visual-analogue scale 
in the physician’s or parent’s global assessment 
of disease activity, and a C-reactive protein level 
of 30 mg per liter)18,23,29; or discontinuation of 
treatment, except in the case of discontinuation 
because of inactive disease at 24 weeks or more.
Patients were also evaluated for higher levels 
of improvement, including adapted JIA ACR 50, 
JIA ACR 70, JIA ACR 90, and JIA ACR 100 re-
sponses (defined as absence of fever plus improve-
ments of ≥50%, ≥70%, ≥90%, and 100%, respec-
tively, in at least three of the six response 
variables and a worsening of >30% in no more 
than one of the six variables), and inactive dis-
ease (i.e., absence of active arthritis, fever, and 
signs or symptoms of systemic JIA; normal C-re-
active protein level; and physician’s global as-
sessment of disease activity of ≤10 mm).23,30-33 
Safety assessments included the collection of data 
on adverse events and serious adverse events. The 
primary outcome evaluation and assessments of 
flare, inactive disease, and glucocorticoid-taper-
ing recommendations were performed in real 
time, according to validated criteria,23,24,29,30 by 
independent evaluators at the PRINTO and PRCSG 
coordinating centers who were unaware of the 
study assignments.
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STATISTICAL ANALYSIS
The trials followed the recommendation of the 
Consolidated Standards of Reporting Trials 
(CONSORT) statement,34 with results reported 
for the intention-to-treat population. Baseline 
characteristics were summarized with the use of 
descriptive statistics. The adapted JIA ACR level 
of improvement was calculated with reference to 
the day of the first injection of canakinumab, 
whereas flare was assessed with respect to the 
core-set variables on the day of randomization in 
the withdrawal phase of trial 2. Patients who 
withdrew from trial 2 were considered not to 
have a response from date of withdrawal onward.
For trial 1, we calculated that a sample of 122 
patients would be required for the trial to have 
90% power to detect a 30% difference in the 
proportions of patients with an adapted JIA ACR 
30 response, at a one-sided significance level of 
0.025. The trial was terminated early on the rec-
ommendation of the independent data and safety 
monitoring committee on the basis of one in-
terim analysis (according to a priori rules in the 
protocol amendment), showing that the primary 
end point had been achieved at a significance level 
of 0.00697. For trial 2, to achieve 90% power, a 
total of 37 events (flares) were needed in the 
withdrawal phase (13 events in the cana kinumab 
group and 24 in the placebo group). We estimated 
that 214 patients would need to be enrolled in 
the open-label phase in order to randomly assign 
58 patients to study groups in the withdrawal 
phase.
R ESULT S
STUDY POPULATION
Table 1 summarizes the baseline disease char-
acteristics for a total of 190 unique participants. 
Baseline characteristics were balanced between 
the two treatment groups in trial 1 and in trial 2, 
according to the randomization in the with-
drawal phase. More than two thirds of the pa-
tients had received biologic agents previously. 
Figure S2 in the Supplementary Appendix shows 
the study-group assignments in the two trials. 
In the open-label phase of trial 2, a total of 77 
of 177 patients (44%) discontinued the study or 
entered the ongoing open-label extension phase; 
the most frequently reported reasons were lack 
of response to therapy by day 29 (in 34 patients) or 
an inability to undergo glucocorticoid tapering 
(in 24). A total of 144 of 177 patients (81%) en-
tered the ongoing, long-term, open-label extension 
study.
EFFICACY
At day 15 of trial 1, a total of 36 patients in the 
canakinumab group (84%), as compared with 4 
in the placebo group (10%), had an adapted JIA 
ACR 30 response, which was sustained at day 29 
(P<0.001) (Fig. 1A). At the end of the open-label 
phase of trial 2, after a median of 113 days and a 
median of four injections of canakinumab, 128 of 
175 patients (73%) had at least an adapted JIA 
ACR 50 response, and 55 of 176 (31%) had inac-
tive disease. A total of 100 of 177 patients (56%) 
underwent glucocorticoid tapering, had at least 
an adapted JIA ACR 30 response, and were eligi-
ble to undergo randomization in the withdrawal 
phase of trial 2. Denominators differ because as-
sessments were missing for some patients at some 
end points.
In the withdrawal phase, the median time to 
flare was 236 days (95% confidence interval [CI], 
141 to 449) in the placebo group; the median 
was not observable in the canakinumab group, 
since less than 50% of the patients had a flare 
(P = 0.003 by the log-rank test) (Fig. S3 in the 
Supplementary Appendix). A total of 39 patients 
in the canakinumab group (74%, according to 
the Kaplan–Meier estimate) had no flare, as com-
pared with 24 in the placebo group (25%, ac-
cording to the Kaplan–Meier estimate), with a 
significant relative risk reduction of 64% with 
regard to flare. At the end of the withdrawal 
phase, a total of 31 of 50 patients in the cana-
kinumab group (62%) had inactive disease, as 
compared with 17 of 50 in the placebo group 
(34%) (Fig. 1B). Table 2 shows the changes over 
time in the JIA core-set measures and clinical 
features for the patients in the two trials (see 
Table S2 in the Supplementary Appendix for a 
list of laboratory tests).
GLUCOCORTICOID TAPERING
Glucocorticoids were prescribed for 128 of the 
177 patients (72%) at study entry, with 57 of these 
128 patients (45%; 90% CI, 37 to 52; P<0.001) 
able to undergo glucocorticoid tapering from a 
mean dose of 0.34 mg per kilogram per day to 
0.05 mg per kilogram per day. A total of 42 of the 
128 patients (33%) discontinued glucocorticoids 
completely.
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SAFETY
Table 3 summarizes adverse events that occurred 
during the two trials. No patient in trial 1 dis-
continued the study because of an adverse event; 
in the withdrawal phase of trial 2, three patients 
in the placebo group withdrew because of a seri-
ous adverse event (the macrophage activation 
syndrome, pneumonia, and flare of systemic JIA). 
Another three patients in the placebo group 
withdrew because of nonserious adverse events 
(vomiting, rash, and uveitis).
In trial 1, two serious adverse events were 
reported in each group. In the canakinumab 
group, there was one episode each of the macro-
phage activation syndrome and varicella; in the 
placebo group, there was one episode each of 
the macrophage activation syndrome and gastro-
enteritis.
In the open-label phase of trial 2, seven pa-
tients had serious nonopportunistic infections: 
two were associated with the macrophage activa-
tion syndrome, and five resolved within 2 weeks.
In the withdrawal phase, serious adverse events 
occurred in six patients in the canakinumab group 
(arm pain and lymphadenopathy in one; otitis me-
dia and leg fracture in one; leukopenia, thrombo-
cytopenia, and aminotransferase elevations in one; 
aminotransferase elevations in one; respiratory 
tract infection in one; and splenic cyst in one); 
none of these events led to discontinuation of the 
study drug. Serious adverse events occurred in six 
patients who received placebo (the macrophage 
Table 1. Demographic and Baseline Clinical Characteristics of the Study Participants.*
Characteristic Trial 1
Trial 2,  
Open- Label Phase
Trial 2,  
Withdrawal Phase
Canakinumab
(N = 43)
Placebo
(N = 41)
Canakinumab
(N = 177)
Canakinumab
(N = 50)
Placebo
(N = 50)
Sex — no. (%)
Male 16 (37) 18 (44) 79 (45) 22 (44) 23 (46)
Female 27 (63) 23 (56) 98 (55) 28 (56) 27 (54)
Race — no. (%)†
White 40 (93) 37 (90) 151 (85) 41 (82) 42 (84)
Black 2 (5) 0 7 (4) 2 (4) 1 (2)
Other 1 (2) 4 (10) 19 (11) 7 (14) 7 (14)
Age — yr
Median 8.0 9.0 8.0 8.0 8.0
Interquartile range 4.0–13.0 6.0–14.0 5.0–12.0 6.0–12.0 5.0–13.0
Body weight — kg
Median 22.2 27.2 25.8 28.6 25.9
Interquartile range 15.1–47.9 21.0–45.5 17.8–42.9 19.8–44.0 18.6–49.4
Disease duration — yr
Median 2.3 2.0 2.1 2.7 1.8
Interquartile range 1.0–4.7 1.2–5.2 0.8–4.3 1.3–6.2 0.4–4.3
Use of methotrexate at baseline — no. (%) 29 (67) 24 (59) 93 (53) 28 (56) 26 (52)
Prior use of biologic agent — no. (%)‡ 25 (58) 23 (56) 116 (66) 30 (60) 27 (54)
Anakinra 16 (37) 15 (37) 83 (47) 25 (50) 20 (40)
Tocilizumab 1 (2) 2 (5) 10 (6) 4 (8) 1 (2)
Anti-TNF agent or other biologic agent 14 (33) 16 (39) 62 (35) 14 (28) 12 (24)
Prednisone therapy at baseline — no. (%) 31 (72) 28 (68) 128 (72) 32 (64) 30 (60)
* There were no significant differences between the two treatment groups in trial 1 and in trial 2, according to the ran-
domization in the withdrawal phase.
† Race was determined by the investigators.
‡ A patient could have received one or more biologic agents previously. TNF denotes tumor necrosis factor.
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activation syndrome and urosepsis in one, measles 
and pneumonia in one, traumatic fracture in two, 
and flare of systemic JIA in two); three of these 
patients (one of the two patients with a disease 
flare, the patient with the macrophage activation 
syndrome and urosepsis, and the patient with 
measles and pneumonia) discontinued the study 
drug because of the event. There were no cases of 
cancer, tuberculosis, or opportunistic infection in 
either trial. Anti-canakinumab antibodies were 
detected in four patients; none were neutralizing.
In trial 1, thrombocytopenia developed in 
2 patients in the canakinumab group (5%) and 
in 1 of 38 patients in the placebo group (3%), 
and neutropenia developed in 2 patients in the 
canakinu mab group (5%) and none in the pla-
cebo group. In the open-label phase of trial 2, a 
total of 11 of 176 patients with assessments (6%) 
had thrombocytopenia, and 10 of 176 (6%) had 
neutropenia. In the withdrawal phase of trial 2, 
a total of 3 patients in the canakinumab group 
(6%) and 1 in the placebo group (2%) had 
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Figure 1. Response to Treatment.
Panel A shows the rates of adapted American College of Rheumatology (ACR) responses for the core set of variables for systemic juve-
nile idiopathic arthritis ( JIA) and inactive disease status in trial 1 (single dose of canakinumab vs. placebo). The adapted JIA ACR 30, JIA 
ACR 50, JIA ACR 70, JIA ACR 90, and JIA ACR 100 responses were defined as improvements of at least 30%, 50%, 70%, 90%, and 100%, 
respectively, in at least three of the six response variables and a worsening of more than 30% in no more than one of the six variables, as 
well as absence of fever. P<0.001 for all comparisons of JIA ACR responses; P values were not determined for comparisons regarding in-
active disease. Panel B shows the rates of adapted JIA ACR responses and inactive disease status in trial 2, both at the end of the open-
label phase and at the end of the withdrawal phase, which included data from the last observation of patients who had had a response.
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thrombocytopenia; 6 patients in the canakinumab 
group (12%) and 1 in the placebo group (2%) had 
neutropenia. One patient had both neutropenia 
and thrombocytopenia and another had throm-
bocytopenia during the macrophage activation 
syndrome. Laboratory abnormalities resolved 
within a mean of 33 days in all patients for 
whom follow-up data were available.
Table 2. Change over Time in the Six Variables of the Juvenile Idiopathic Arthritis Core Set and in Systemic Features.*
Variable Trial 1 Trial 2
Baseline End of Trial Baseline
End of Open-
Label Phase End of Withdrawal Phase
Placebo
(N = 41)
Canakinumab
(N = 43)
Canakinumab
(N = 38)
Canakinumab
(N = 177)
Canakinumab
(N = 100)
Canakinumab
(N = 50)
Placebo
(N = 50)
No. of joints with active arthritis†
Median 7.0 10.0 1.0 10.0 0.0 0.0 0.0
Interquartile range 4.0–19.0 4.0–24.0 0–6.0 4.0–22.0 0.0–2.0 0.0–2.0 0.0–4.0
No. of joints with limited range  
of motion‡
Median 6.0 8.0 2.0 9.0 0.0 0.0 1.0
Interquartile range 4.0–22.0 4.0–19.0 0.0–8.0 4.0–23.0 0.0–2.0 0.0–2.0 0.0–4.0
Score for physician’s global assessment 
of disease activity§
Median 66.0 67.0 11.0 70.0 0.0 0.0 6.5
Interquartile range 55.0–80.0 55.0–80.0 1.0–29.0 55.0–80.0 0.0–6.0 0.0–7.0 0.0–30.0
Score for parent’s global assessment  
of patient’s overall well-being¶
Median 61.0 63.0 6.5 63.5 2.0 1.0 3.0
Interquartile range 35.0–81.0 45.0–81.0 0.0–26.0 45.0–80.0 0.0–12.0 0.0–7.0 1.0–30.0
CHAQ-DI score‖
Median 1.5 1.6 0.2 1.8 0.0 0.0 0.1
Interquartile range 1.0–2.1 1.1–2.3 0.0–0.9 1.1–2.3 0.0–0.4 0.0–0.4 0.0–1.0
C-reactive protein**
Median 137.0 141.3 12.0 160.0 5.3 5.0 17.9
Interquartile range 71.2–194.9 88.0–270.0 3.3–76.6 88.0–271.0 1.8–16.5 1.2–10.0 3.3–68.0
Systemic features — no./total no. (%)††
Fever‡‡ 39/41 (95) 42/43 (98) 5/43 (12) 161/177 (91) 0/100 3/50 (6) 9/50 (18)
Rash 24/41 (59) 20/43 (47) 4/43 (9) 79/177 (45) 1/100 (1) 3/50 (6) 9/50 (18)
*  Data are shown for patients who received canakinumab in trial 1 and trial 2. However, only baseline values are provided for patients who 
received placebo in trial 1, since 37 of 41 patients in the placebo group (90%) discontinued the study drug prematurely and were immedi-
ately enrolled in trial 2.
†  The range of possible values for number of joints with active arthritis was 0 to 73.21
‡  The range of possible values for number of joints with limited range of motion was 0 to 69.
§  The physician’s global assessment of disease activity was based on a 100-mm visual-analogue scale, with higher scores indicating more 
active disease.
¶  The parent’s global assessment of the patient’s overall well-being was based on a 100-mm visual-analogue scale, with higher scores indi-
cating more active disease.
‖  Physical function was assessed by means of the cross-culturally adapted and validated version of the Childhood Health Assessment 
Questionnaire–Disability Index (CHAQ-DI), with scores ranging from 0 to 3 and higher scores indicating greater disability.
** The level of C-reactive protein was standardized to the upper limit of the normal range of 10 mg per liter (normal range, 0 to 10 mg per  
liter).24,26-28
†† The total number of patients who were receiving canakinumab at the end of the trial is equal to the total number of patients who under-
went randomization in trial 1 and who were treated with canakinumab. Some patients in trial 2 did not have fever or rash because these 
signs disappeared when they began participating in that trial.
‡‡ Resolution of fever was defined as the documented absence of fever due to systemic JIA (temperature, ≤38°C) in the week preceding the 
assessment, according to documentation in a paper diary.
The New England Journal of Medicine 
Downloaded from nejm.org on November 1, 2016. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
canakinumab in systemic juvenile idiopathic arthritis
n engl j med 367;25 nejm.org december 20, 2012 2403
There were seven reported cases of the macro-
phage activation syndrome (including two cases 
in the placebo group [one during trial 1 and the 
other during the withdrawal phase of trial 2]). 
An independent adjudication committee classified 
five of the cases as probable cases of the macro-
phage activation syndrome and two as possible 
cases. With respect to the two possible cases, 
the committee stated that ferritin levels were low 
for the macrophage activation syndrome in one 
case, and in the other case, the rash was atypical 
and the patient was assessed as having a Klebsiella 
pneumoniae infection.
Two patients died while they were participat-
ing in trial 2. A 16-year-old girl had received 
eight doses of canakinumab, followed by placebo 
for 164 days (six doses); she then had progres-
sive clinical worsening and urosepsis. Clinical, 
laboratory, and bone marrow findings suggested 
the macrophage activation syndrome. While be-
ing transferred to a tertiary care hospital, she 
had a cardiac arrest requiring resuscitation and 
intubation. The findings on chest radiography 
were consistent with the acute respiratory dis-
tress syndrome. The patient died 7 days after the 
transfer to the tertiary care hospital (2 days after 
withdrawal from the study). In addition, a 13-year-
old boy, who had previously been treated with 
anakinra and tocilizumab, died during study 
participation. The child was hospitalized for an 
Table 3. Adverse Events in the Two Trials.*
Event Trial 1
Trial 2,  
Open-Label Phase
Trial 2,  
Withdrawal Phase
Canakinumab
(N = 43)
Placebo
(N = 41)
Canakinumab
(N = 177)
Canakinumab
(N = 50)
Placebo
(N = 50)
Total no. of adverse events 49 27 664 272 229
Patients with event — no. (%) 24 (56) 16 (39) 138 (78) 40 (80) 35 (70)
Rate per 100 patient-days† NA NA NA 2.34 2.53
Patients with serious adverse event — no. (%) 2 (5) 2 (5) 15 (8) 6 (12) 6 (12)
Patients with adverse event leading to with-
drawal — no. (%)
0 0 5 (3) 0 6 (12)
Infection
Patients with event — no. (%) 13 (30) 5 (12) 97 (55) 27 (54) 19 (38)
Rate per 100 patient-days† NA NA NA 0.59 0.63
Patients with serious infection — no. (%) 2 (5) 1 (2) 7 (4) 2 (4) 2 (4)
Macrophage activation syndrome — no. (%) 1 (2) 1 (2) 4 (2) 0 1 (2)
Death — no. (%) 0 0 1 (1) 0 1 (2)‡
Most frequently reported events — no. (%)§
Abdominal pain 3 (7) 1 (2) 26 (15) 8 (16) 6 (12)
Cough 1 (2) 0 20 (11) 8 (16) 6 (12)
Headache 2 (5) 1 (2) 23 (13) 3 (6) 3 (6)
Nasopharyngitis 3 (7) 1 (2) 27 (15) 7 (14) 7 (14)
Pyrexia 2 (5) 0 18 (10) 7 (14) 5 (10)
Upper respiratory tract infection 3 (7) 0 18 (10) 6 (12) 5 (10)
Vomiting 1 (2) 1 (2) 18 (10) 1 (2) 4 (8)
* The rates of adverse events and serious adverse events per patient-year were not calculated for trial 1 or for the open-
label phase of trial 2; these analyses were not planned because of the short duration of the trial or phase and the small 
number of patients in the placebo group. NA denotes not available.
† The frequency of adverse events in trial 1 in the placebo and canakinumab groups must be interpreted with consider-
ation of the median period of study participation, which was 8 days in the placebo group as compared with 29 days in 
the canakinumab group.
‡ This patient died 7 days after transfer to a tertiary care hospital (2 days after withdrawal from the study).
§ The most frequently reported events were defined as those that occurred in at least 10% of patients during the open-label 
phase of trial 2.
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episode of adenovirus gastroenteritis, which re-
solved within 14 days. Four days later, after 
receiving the third dose of canakinumab, he was 
rehospitalized for the macrophage activation 
syndrome; severe pulmonary hypertension devel-
oped, and he died 3 weeks later.
In addition, two deaths occurred outside the 
studies. A 9-year-old girl died from disease pro-
gression approximately 3 months after trial dis-
continuation because of an unsatisfactory thera-
peutic effect. A 19-year-old woman died more 
than 2 years after receiving the last dose of 
canakinumab in the phase 2 trial18; the patient’s 
cerebrospinal-fluid and blood cultures were pos-
itive for Streptococcus pneumoniae.
DISCUSSION
We conducted two parallel studies to assess the 
efficacy and safety of canakinumab in the treat-
ment of systemic JIA with active systemic fea-
tures. The rationale for trial 1 was to provide 
evidence that the drug is effective in controlling 
fever within a few days after administration. For 
ethical reasons, patients in this trial who had 
persistent fever 3 days after the first injection 
were permitted, at the discretion of the physi-
cian, to be made aware of their study assignment 
in an effort to rapidly provide access to open-label 
treatment in trial 2. The rationale for trial 2 was 
to investigate the glucocorticoid-tapering poten-
tial and the prevention of disease flare during up 
to 2 years of treatment.
In trial 1, a single injection of canakinumab 
resulted in inactive disease in as few as 15 days 
in 33% of the patients, confirming the prelimi-
nary results of the phase 2 dose-finding study.18 
The results of trial 1 were corroborated by those 
of trial 2, which showed that 31 (62%) of 50 pa-
tients continuously treated with canakinumab 
had inactive disease status and 41 (82%) had at 
least an adapted JIA ACR 70 response after 2 years 
of treatment. These findings confirm, in a con-
trolled setting, previous observations with 
anakinra,11-13,18,35 which suggested that about 
40% of patients with systemic JIA have a dramatic 
and persistent response to anti–interleukin-1 ther-
apy. This is similar to response rates observed in 
some autoinflammatory diseases15,17,35-37 and 
in trials with anti–interleukin-6 medications.8-10
In trial 2, the open-label phase lasted for 32 
weeks to allow tapering of glucocorticoids to a 
safe dose, which then remained stable during 
the subsequent double-blind withdrawal phase. 
Canakinumab allowed for the discontinuation 
of glucocorticoids in 33% of the patients within 
7 months after treatment, decreasing the burden 
of glucocorticoid toxicity among patients with a 
disease that often results in dependence on glu-
cocorticoids. In the withdrawal phase, the medi-
an time to flare was 8 months in the placebo 
group (95% CI, 5 to 15), whereas the median time 
to flare could not be estimated for the canakinum-
ab group, owing to the low number of flares that 
had occurred at the time of study completion.18
For all treatment groups, the most common 
adverse events were infections. The crude inci-
dence rate of infection during treatment with 
canakinumab was similar to that with placebo 
in these trials. Neutropenia and thrombocytope-
nia were observed in both trials and were mostly 
transient, isolated events that were not associ-
ated with an increased risk of infection or bleed-
ing. Seven cases of the macrophage activation 
syndrome were reported in these trials, with two 
associated deaths.38,39 The mortality rate in 
phase 218 and phase 3 trials of canakinumab 
(2% over an average of 547 days) is in line with 
the mortality rate associated with systemic JIA, 
as reported by Hashkes et al.40
A limitation of the two studies is that patients 
without fever were excluded from participation. 
Indeed, in a subset of patients with systemic JIA, 
systemic symptoms eventually resolve while 
chronic arthritis continues. Therefore, the effi-
cacy of canakinumab in patients who have sys-
temic JIA without fever cannot be deduced di-
rectly from our results. In addition, information 
on the safety of canakinumab in patients with 
systemic JIA is limited, given the short duration 
of exposure to placebo in both trials and the use 
of a withdrawal design.23,41,42 Longer-term safety 
data are needed.
In conclusion, these two placebo-controlled tri-
als show the efficacy of canakinumab in the treat-
ment of systemic JIA with active systemic features.
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